Current options for slowing the progression of chronic kidney disease

Czech version

Authors: Vladimír Tesař
Authors‘ workplace: Klinika nefrologie 1. LF UK a VFN Praha
Published in: Vnitř Lék 2022; 68(7): 420-424
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.089

Overview

From a certain stage, chronic kidney disease progresses to terminal kidney failure that requires renal replacement therapy with dialysis or transplantation. The progression can be significantly slowed by blocking the renin angiotensin aldosterone system (RAAS) with angiotensin converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers (ARB). Another new option to enhance the effect of blocking the RAAS system is the use of sodium glucose cotransporter 2 (SGLT2) inhibitors, or gliflozins. Dapagliflozin is currently available and reimbursed for patients with both diabetic and non-diabetic kidney disease. In the near future, treatment with the mineralocorticoid receptor inhibitor finerenone should be made available that significantly potentiates the effect of ACE or ARB inhibitors. Recent data show that it is possible to influence the progression of renal insufficiency with exercise.

Keywords:

SGLT2 – exercise – dapagliflozin – SGLT2 inhibitor – progression of chronic kidney disease – finerenone – renin angiotensin system – mineralocorticoid receptor

Sources

1. Brenner BM, Meyer RW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 1982,307 : 652-9.

2. Parving HH, Lehnert H, Brochner‑Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med.2001,345 : 870-8.

3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001,345 : 861-9.

4. Lewis EJ, Husicker LG., Clarke WR et al. Renoprotective effect of the angiotensin‑receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001,345 : 851-60.

5. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004,351 : 1941-51.

6. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin‑converting‑enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensi‑Converting‑Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med.1996, 354 : 939-45.

7. GISEN Group: Randomised placebo‑controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non‑diabetic nephropathy. Lancet. 1997,349 : 1857-63.

8. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 2013,369 : 1892-1903.

9. Bakris GL, Agarwa lR, Anker SD et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 2020, October 23, doi: 10.1056/NEJMoa2025845.

10. Ruilope LM, Pitt B, Anker SD et al. Kidney outcomes with finerenone: an analysis from FIGARO‑DKD study. Nephrol. Dial. Tranplant, 2022. doi: 10.1093/ndt/gfac157.

11. Agarwa lR, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 2022;43 : 474-484.

12. Perkovic V, Jardine MJ, Nea lB et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019;380 : 2295-306.

13. Heerspink HJL, Stefánsson BV, Correa‑Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383 : 1436-1446.

14. Agarwa lR, Anker SD, Filippatos G et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO‑DKD compared to reported CREDENCE results. Nephrol. Dial. Transplant. 2022;37 : 1261-1269.

15. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized controlled trial. JAMA. 2019;321 : 69-79.

16. Tuttle KR, Lakshmanan MC, Rayner B et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate‑to‑severe chronic kidney disease (AWARD-7): a multicentre, open‑label, randomised trial. Lancet Diabetes Endocrinol. 2018;6 : 605-617.

17. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‑controlled trial. Lancet. 2019;394 : 1312-138.

18. Shlipak MG, Sheshadri A, Hsu FC et al. Effect of structured, moderate exercise on kidney function declline in sedentary older adults: an ancillary analysis of the LIFE study randomized clinical trial. JAMA Intern. Med. 2022;182 : 650-659.